Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Prepaid Assets (2017 - 2025)

Historic Prepaid Assets for Aclaris Therapeutics (ACRS) over the last 9 years, with Q2 2025 value amounting to $4.2 million.

  • Aclaris Therapeutics' Prepaid Assets fell 3241.11% to $4.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.2 million, marking a year-over-year decrease of 3241.11%. This contributed to the annual value of $12.0 million for FY2024, which is 2736.99% up from last year.
  • According to the latest figures from Q2 2025, Aclaris Therapeutics' Prepaid Assets is $4.2 million, which was down 3241.11% from $3.2 million recorded in Q1 2025.
  • Over the past 5 years, Aclaris Therapeutics' Prepaid Assets peaked at $19.7 million during Q3 2023, and registered a low of $3.2 million during Q1 2025.
  • In the last 5 years, Aclaris Therapeutics' Prepaid Assets had a median value of $9.0 million in 2021 and averaged $9.3 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first soared by 40173.75% in 2021, then tumbled by 7831.72% in 2024.
  • Aclaris Therapeutics' Prepaid Assets (Quarter) stood at $13.0 million in 2021, then increased by 3.85% to $13.5 million in 2022, then fell by 29.96% to $9.5 million in 2023, then increased by 27.37% to $12.0 million in 2024, then tumbled by 65.1% to $4.2 million in 2025.
  • Its Prepaid Assets was $4.2 million in Q2 2025, compared to $3.2 million in Q1 2025 and $12.0 million in Q4 2024.